as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹1,513.6
Change
-12.9 (-0.85%)
Open
₹1,528.0
Prev. Close
₹1,526.5
Day High
₹1,540.0
Day Low
₹1,504.0
Volume Analysis
Traded
58,184
Delivered
29,585
Delivery %
50.85%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (42.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year EPS growth (26.6%)
- •Strong 3-year revenue growth (21.0%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,570.4 | ₹1,555.2 | ₹1,534.4 | ₹1,519.2 | ₹1,498.4 | ₹1,483.2 | ₹1,462.4 |
| Fibonacci | ₹1,555.2 | ₹1,541.45 | ₹1,532.95 | ₹1,519.2 | ₹1,505.45 | ₹1,496.95 | ₹1,483.2 |
| Camarilla | ₹1,523.5 | ₹1,520.2 | ₹1,516.9 | ₹1,519.2 | ₹1,510.3 | ₹1,507.0 | ₹1,503.7 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+45.2%
1 Week
-2.73%
1 Month
+4.21%
3 Months
+11.9%
6 Months
+71.12%
1 Year
+48.41%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹187.55
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
18.5%
Net margin 21.82% × asset turnover 0.54x × equity multiplier 1.57x
Company Overview
Sector
Healthcare
Market Cap
₹15,590 Cr
P/E (TTM)
83.2
ROE
18.3%
Book Value
₹93.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.
TopFund Analysis
Vijaya Diagnostic Cen Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 71/100. The strongest factor is Financial Strength (92/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (42.0%); promoter holding is falling. FII holding has been falling.
TopFund Score — Fundamentals Quality
71/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Stock is trading at 16.3 times its book value
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
100% acquisition of integrated diagnostic business undertaking of Arya Wellness Centre, Guwahati, Assam.
Vijaya Diagnostic to acquire Arya Wellness Centre, Guwahati, for ~₹46 crore; closure expected in three months.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 121 | 139 | 133 | 155 | 156 | 183 | 169 | 173 | 188 | 202 | 205 | 219 | 231 |
| Expenses + | 73 | 82 | 80 | 92 | 95 | 107 | 102 | 104 | 115 | 120 | 119 | 124 | 132 |
| Operating Profit | 48 | 57 | 52 | 63 | 61 | 76 | 67 | 69 | 74 | 82 | 86 | 96 | 99 |
| OPM % | 40.0% | 41.0% | 39.0% | 41.0% | 39.0% | 42.0% | 40.0% | 40.0% | 39.0% | 41.0% | 42.0% | 44.0% | 43.0% |
| Other Income + | 6 | 7 | 3 | 3 | 4 | 5 | 5 | 5 | 7 | 6 | 5 | 2 | 9 |
| Interest | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 9 | 9 | 11 |
| Depreciation | 12 | 14 | 15 | 16 | 17 | 17 | 18 | 19 | 21 | 22 | 24 | 24 | 25 |
| Profit before tax | 35 | 45 | 35 | 44 | 42 | 57 | 47 | 47 | 52 | 58 | 58 | 64 | 71 |
| Tax % | 26.0% | 25.0% | 25.0% | 23.0% | 25.0% | 26.0% | 24.0% | 26.0% | 26.0% | 25.0% | 26.0% | 25.0% | 25.0% |
| Net Profit + | 26 | 34 | 26 | 34 | 32 | 42 | 35 | 35 | 39 | 43 | 43 | 48 | 53 |
| EPS in Rs | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 5 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 251 | 293 | 339 | 377 | 462 | 459 | 548 | 681 | 814 | 857 |
| Expenses + | 171 | 184 | 206 | 211 | 259 | 277 | 327 | 408 | 477 | 495 |
| Operating Profit | 80 | 108 | 133 | 166 | 204 | 182 | 221 | 273 | 337 | 362 |
| OPM % | 32.0% | 37.0% | 39.0% | 44.0% | 44.0% | 40.0% | 40.0% | 40.0% | 41.0% | 42.0% |
| Other Income + | 7 | 10 | 15 | 12 | 13 | 14 | 19 | 17 | 21 | 22 |
| Interest | 5 | 14 | 15 | 15 | 16 | 21 | 24 | 27 | 33 | 37 |
| Depreciation | 26 | 40 | 49 | 50 | 53 | 62 | 57 | 71 | 92 | 96 |
| Profit before tax | 55 | 65 | 83 | 112 | 147 | 114 | 159 | 193 | 233 | 251 |
| Tax % | 37.0% | 29.0% | 25.0% | 24.0% | 25.0% | 25.0% | 25.0% | 26.0% | 26.0% | — |
| Net Profit + | 35 | 46 | 63 | 85 | 111 | 85 | 120 | 144 | 173 | 187 |
| EPS in Rs | 77 | 101 | 138 | 19 | 11 | 8 | 12 | 14 | 17 | 18 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 9.0% | 12.0% | 9.0% | 14.0% | 12.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Reserves | 157 | 203 | 270 | 354 | 458 | 535 | 647 | 789 | 947 |
| Borrowings + | 33 | 146 | 161 | 141 | 183 | 248 | 259 | 320 | 423 |
| Other Liabilities + | 39 | 53 | 46 | 41 | 62 | 61 | 66 | 155 | 127 |
| Total Liabilities | 234 | 406 | 482 | 541 | 713 | 853 | 983 | 1,274 | 1,507 |
| Fixed Assets + | 119 | 259 | 272 | 268 | 370 | 524 | 742 | 865 | 1,069 |
| CWIP | 3 | 3 | 10 | 9 | 34 | 28 | 9 | 70 | 35 |
| Investments | 73 | 69 | 55 | 28 | 54 | 139 | 109 | 185 | 228 |
| Other Assets + | 39 | 76 | 146 | 236 | 255 | 163 | 123 | 154 | 174 |
| Total Assets | 234 | 406 | 482 | 541 | 713 | 853 | 983 | 1,274 | 1,507 |
| Equity Capital | 5 | 5 | 5 | 5 | 10 | 10 | 10 | 10 | 10 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 62 | 91 | 106 | 130 | 158 | 165 | 183 | 224 | 271 |
| Cash from Investing Activity + | -98 | -90 | -31 | -130 | -123 | -110 | -141 | -182 | -174 |
| Cash from Financing Activity + | -8 | -7 | -30 | -49 | -31 | -42 | -45 | -52 | -69 |
| Net Cash Flow | -44 | -6 | 46 | -49 | 4 | 13 | -2 | -9 | 27 |
| CFO/OP | 103 | 101 | 98 | 97 | 97 | 105 | 98 | 97 | 96 |
| Free Cash Flow | 32 | 31 | 69 | 98 | 37 | 40 | 99 | 132 | 91 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 5.78% | 5.36% | 5.03% | 4.5% | 4.49% | 3.92% | 3.86% | 3.73% | 3.77% | 3.7% | 4.17% | 4.22% |
| Promoters | 54.9% | 54.87% | 54.06% | 53.92% | 53.91% | 53.91% | 53.05% | 52.63% | 52.6% | 52.6% | 52.51% | 52.51% |
| FII | 20.68% | 19.95% | 20.09% | 20.08% | 18.14% | 17.54% | 19.36% | 19.56% | 18.27% | 15.1% | 13.38% | 11.65% |
| DII | 18.64% | 19.82% | 20.8% | 21.49% | 23.45% | 24.62% | 23.72% | 24.07% | 25.34% | 28.6% | 29.93% | 31.61% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Vijaya Diagnostic Cen Ltd (this stock) | 15,590 | 83.2 | 16.28 | 18.3% |
| Dr Agarwals Health Care L | 15,686 | 106.0 | 7.75 | 5.99% |
| Syngene International Ltd | 15,287 | 51.6 | 3.16 | 7.78% |
| Marksans Pharma Limited | 15,269 | 29.6 | 5.05 | 15.2% |
| Molbio Diagnostics Ltd | 15,118 | 60.6 | — | 15.6% |
| Concord Biotech Limited | 16,142 | 58.1 | 7.99 | 12.5% |
| Natco Pharma Ltd. | 15,033 | 13.1 | 1.63 | 17.1% |
Which Mutual Funds Hold Vijaya Diagnostic Cen Ltd?
Frequently Asked Questions about Vijaya Diagnostic Cen Ltd
Vijaya Diagnostic Cen Ltd (VIJAYA) closed at ₹1,513.6 on NSE on 25 September 2026, down 12.9 (0.85%) from the previous close.
Vijaya Diagnostic Cen Ltd trades on the NSE (National Stock Exchange of India) under the symbol VIJAYA.
Vijaya Diagnostic Cen Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 83.2.
Vijaya Diagnostic Cen Ltd has a dividend yield of 0.13%.
Vijaya Diagnostic Cen Ltd's 52-week high is ₹1,594.0 and its 52-week low is ₹848.0.
Vijaya Diagnostic Cen Ltd has a market capitalisation of ₹15,590 crore.
Vijaya Diagnostic Cen Ltd has a TopFund Quality Score of 71/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Vijaya Diagnostic Cen Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.